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Abstract
Drug-eluting stents (DES) are designed to release 
pharmacological agents into the vessel wall in order 
to inhibit the response to injury causing restenosis, 
i.e., vascular smooth muscle cell migration and prolif-
eration. Once deployed, however, these substances 
exert many biological effects in the coronary circula-
tion; their action is indeed not confined to inhibition 
of vascular smooth muscle cells, but extends to other 
cell types such as endothelial cells. Both rapamycin 
and paclitaxel decrease endothelial cell migration 
and proliferation; moreover, they induce tissue factor 
expression through specific interaction with signal 
transduction mediators. As both effects would lead to 
an increased thrombogenic potential of DES, they ap-
pear particularly important in light of a possibly in-
creased risk for stent thrombosis with DES as com-
pared to bare-metal stents. This aspect is further 
highlighted by the observation that DES also decrease 
proliferation, differentiation, and homing of endothe-
lial progenitor cells, which are believed to contribute 
to reendothelialization after stent implantation. Fur-
thermore, both rapamycin and paclitaxel have been 
demonstrated to induce endothelial dysfunction in 
the coronary vasculature distal to the stent. Finally, 
the polymer used for DES may be associated with hy-
persensitivity reactions, which may, at least in some 
cases, favor stent thrombosis. This review will discuss 
the biological effects of DES in the coronary vascula-
ture.
Biologische Effekte von Drug-eluting-Stents im koronaren Gefäßbett
 Zusammenfassung
Drug-eluting-Stents (DES) setzen nach ihrer Implan-
tation pharmakologische Substanzen in die Gefäß-
wand frei, welche die zur Restenose führenden Pro-
zesse – Migration und Proliferation glatter Gefäß-
muskelzellen – inhibieren. Die Wirkung dieser 
Pharmaka ist jedoch vielfältig und zudem nicht auf 
glatte Gefäßmuskelzellen beschränkt; so inhibieren 
sowohl Rapamycin als auch Paclitaxel die Migration 
und Proliferation von Endothelzellen und induzieren 
außerdem die Expression von Tissue-Faktor durch 
spezifische Interaktion mit Mediatoren der Signal-
transduktion. Da diese beiden Effekte zu einer erhöh-
ten Stentthrombogenität führen können, erscheinen 
sie von großer Wichtigkeit, insbesondere im Rahmen 
der aktuellen Diskussion um eine möglicherweise er-
höhte Rate von Stentthrombosen bei DES im Vergleich 
zu unbeschichteten Bare-Metal-Stents. Hinzu kommt, 
dass sowohl Rapamycin als auch Paclitaxel die Prolife-
ration, Migration und Differenzierung von endothe-
lialen Progenitorzellen, welche ebenfalls zur Reendo-
thelialisierung nach Stentimplantation beizutragen 
scheinen, hemmen. Darüber hinaus konnte gezeigt 
werden, dass beide Substanzen in Gefäßsegmenten 
distal der gestenteten Läsion eine endotheliale Dys-
funktion induzieren. Schließlich kann das Polymer, 
welches zur Beschichtung verwendet wird, zu Hyper-
sensitivitätsreaktionen in der Gefäßwand führen, 
was zumindest in manchen Fällen die Entstehung ei-
ner Stentthrombose zu begünstigen scheint. Dieser 
Übersichtsartikel beleuchtet die biologischen Effekte 
von DES im koronaren Gefäßbett.
Schlüsselwörter:  
Drug-eluting-Stents · 
Restenose · Thrombose ·
Tissue-Faktor · Endo-
theliale Regeneration
Key Words:  
Drug-eluting stent · 
Restenosis · Throm-
bosis · Tissue
factor · Endothelial 
regeneration
1 Cardiology, Car-
diovascular Center, 
University Hospital 
Zurich, Cardiovas-
cular Research, 
Physiology Insti-
tute, University of 
Zurich, and Center 
for Integrative Hu-
man Physiology, 
University of Zur-
ich, Switzerland.
Herz 2007;32:268–73
DOI 10.1007/
s00059-007-3000-5
Introduction
With the introduction of balloon-expandable 
bare-metal stents (BMS), coronary remodeling and 
in turn restenosis rates were reduced as compared to 
angioplasty alone [16, 44]. As the risk of restenosis 
remained > 10%, however, drug-eluting stents (DES) 
were designed which release pharmacological agents 
after deployment. On first-generation DES, rapamy-
cin (sirolimus, used on Cypher® stents) or paclitaxel 
(used on Taxus® stents) were applied in order to re-
duce restenosis through inhibition of vascular smooth 
muscle cell (VSMC) migration and proliferation. As 
a result, the rates of restenosis and target vessel re-
vascularization could be reduced to < 10% after DES 
implantation [37, 38].
Already in the first series of patients receiving 
BMS, however, stent thrombosis was recognized as a 
severe complication owing to its high mortality. In-
deed, despite reduced restenosis rates, the incidence 
of in-stent thrombosis has not decreased with DES as 
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compared to BMS [3, 4, 8, 35, 36]. Several hundred 
cases of stent thrombosis have been reported for rapa-
mycin-coated stents [32], and a number of reports im-
ply that thrombosis rates of DES may even be higher 
in “real-world” patients than in clinical trials [27, 40].
This review article focuses on the biological ef-
fects of DES in the coronary circulation.
Biological Effects of Drug-Eluting Stents in 
the Coronary Circulation
DES Impair VSMC Migration and Proliferation
Agents released from DES inhibit migration and pro-
liferation of VSMCs, which are the crucial events in 
neointima formation and the development of reste-
nosis (Figure 1) [33, 42]. In vitro, VSMC proliferation 
is blocked by rapamycin via interference with several 
cell-cycle regulators involved in G1–S phase transi-
tion including p27Kip1 [31], p21cip1 [30], cyclin D iso-
forms, and, finally, the retinoblastoma protein (pRb) 
[33]. Although not fully resolved in detail, the antimi-
gratory effect of rapamycin appears to occur via in-
teraction with p27Kip1 as well [50]. In vivo, rapamycin 
inhibits intimal thickening after balloon angioplasty 
in porcine and rodent animal models through interac-
tion with cell-cycle regulators [17, 43]. The role of 
p27Kip1 in this process, however, remains unclear, as 
some studies imply an effect of rapamycin on this 
protein [17], while others do not [6, 43].
Everolimus, an orally active compound of the si-
rolimus family, is used on second-generation DES 
(Xience®); when applied orally in a rabbit iliac artery 
model, it significantly reduces neointimal growth 
[14]. Similarly, zotarolimus, a synthetic rapamycin 
analog developed specifically for stent application 
(Endeavor®), inhibits VSMC migration and prolifer-
ation and reduces neointima formation in a porcine 
coronary artery model [18].
Paclitaxel, a lipophilic diterpenoid that binds to 
the β-subunit of the tubulin heterodimer, stabilizes 
microtubules, induces cell-cycle arrest in G2–M phase, 
and, eventually, inhibits VSMC migration and prolif-
eration [2, 11, 45]. Consistently, an inhibition of neo-
intima formation is observed in animal models after 
local delivery of paclitaxel [25].
DES Inhibit Endothelial Cell Migration and 
Proliferation
Coronary angioplasty leads to disruption of the endo-
thelial layer leaving a highly prothrombotic surface 
exposed to the blood stream. Restoration of an intact 
endothelium therefore represents a crucial process in 
reestablishing an antithrombotic vessel surface. Tra-
ditionally, it is believed that reendothelialization oc-
curs after vascular injury and stent deployment be-
cause endothelial cells proliferate and migrate from 
intact neighboring coronary segments, eventually 
leading to endothelial healing of the injured seg-
ment.
Given the ubiquitous expression of cell-cycle 
regulatory proteins, it is conceivable that agents re-
leased from DES do not only affect proliferation and 
migration of VSMCs, but also of endothelial cells 
(Figure 1). Indeed, rapamycin potently inhibits endo-
thelial cell proliferation [48] and migration [34] in vi-
tro. Similarly, paclitaxel reduces endothelial cell pro-
liferation and migration through interaction with 
cell-cycle regulators and, at least in part, through in-
duction of apoptosis [41].
In animal models, the time course of reendothe-
lialization after stent implantation varies in differ-
ent species. In pigs, the extent of reendothelializa-
Figure 1. Biological effects of drug-eluting stents (DES) in the coronary circula-
tion.
Simplified overview of the effect of a DES strut on the vessel wall after deploy-
ment. Sirolimus/paclitaxel inhibit vascular smooth muscle cell (VSMC) migration 
and proliferation, thereby reducing restenosis. On the other hand, these drugs in-
hibit migration and proliferation of neighboring endothelial cells (EC), induce tis-
sue factor (TF) expression, and inhibit homing, proliferation, and differentiation of 
endothelial progenitor cells (EPC), potentially leading to an increase in stent 
thrombogenicity. Moreover, the polymer or the stent strut itself may elicit a hy-
persensitivity reaction in the vessel wall.
Abbildung 1. Biologische Effekte von Drug-eluting-Stents (DES) in der Koronarzir-
kulation.
Vereinfachter Überblick über den Effekt von DES auf die Gefäßwand nach Implan-
tation. Sirolimus/Paclitaxel inhibieren die Migration und Proliferation glatter Ge-
fäßmuskelzellen (VSMC) und reduzieren somit die Restenose. Auf der anderen 
Seite inhibieren diese Medikamente ebenfalls die Migration und Proliferation von 
angrenzenden Endothelzellen (EC); des Weiteren induzieren sie die Expression 
von Tissue-Faktor (TF) und inhibieren das „homing“, die Proliferation sowie die 
Differenzierung endothelialer Vorläuferzellen (EPC), was potentiell die Stent-
thrombogenität erhöht. Darüber hinaus kann das Polymer oder das Stentgerüst 
selbst eine Hypersensitivitätsreaktion in der Gefäßwand auslösen.
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tion is similar between BMS and DES after 28 days 
[51]; however, delayed endothelial healing occurs in 
a rabbit iliac overlapping stent model after implan-
tation of sirolimus- or paclitaxel-eluting stents as 
compared to BMS [15]. In humans, near complete 
reendothelialization seems to occur by 3–4 months 
after BMS implantation [13]. In an autopsy study 
comparing coronary artery segments after implanta-
tion of DES with BMS, delayed arterial healing and 
poorer reendothelialization are documented after 
DES implantation [29]. Hence, there is evidence 
that the currently used DES may significantly im-
pair reendothelialization after coronary artery stent 
deployment.
DES Inhibit Homing, Proliferation, and Dif-
ferentiation of Endothelial Progenitor Cells
Endothelial progenitor cells (EPCs) seem to be in-
volved in reendothelialization after angioplasty [19, 
53]; hence, it is important to understand the effect of 
DES on EPC biology. Rapamycin indeed inhibits 
proliferation, migration, and differentiation of hu-
man EPCs in vitro [7, 10]; these effects occur via in-
teraction with the mammalian target of rapamycin 
(mTOR) and, at least in part, by induction of apopto-
sis. It therefore comes as no surprise that, in contrast 
to BMS, implantation of a sirolimus-eluting stent 
leads to a decrease in circulating CD34-positive cells 
[28]. Hence, drugs loaded on DES may affect hom-
ing, proliferation, and differentiation of EPCs there-
by delaying proper endothelial regeneration (Fig -
ure 1).
DES Induce Endothelial Tissue Factor
Expression
On a molecular level, rapamycin binds to the FK-bind-
ing protein 12 (FKBP-12) and thereby inhibits phos-
phorylation of mTOR. mTOR is a downstream target 
of the phosphatidylinositol-3 kinase (PI-3K) path-
way, which in turn regulates translation by phosphor-
ylation of p70S6 ribosomal protein kinase (p70S6K) 
[24]. The inhibitory role of the PI-3K pathway on ex-
pression of endothelial tissue factor (TF) is well es-
tablished, as its inhibition enhances TF expression in 
response to thrombin or tumor necrosis factor-
(TNF-)α [9, 12]. Consistently, inhibition of mTOR by 
rapamycin increases thrombin- as well as TNF-α-
induced endothelial TF expression and activity 
(Figure 2a) [48]. Importantly, this effect occurs at rapa-
mycin concentrations observed in vivo after stent im-
plantation [48, 54]. The effect of rapamycin on TF ex-
pression in VSMCs is controversial: while we did not 
observe an effect after 5 h of incubation [48], prolonged 
exposition (e.g., 24 h) of rapamycin has been demon-
strated to slightly elevate VSMC TF expression [57].
Paclitaxel does not only stabilize microtubules, 
but also activates signal transduction molecules such 
as JNK [46, 55], an important mediator of endothelial 
TF induction [20, 47, 49]. Consequently, paclitaxel 
increases endothelial TF expression and activity (Fig-
ure 2b) [46]; again, the concentrations exerting this 
effect are comparable with local tissue concentrations 
encountered after stent deployment [15].
Sirolimus-eluting stents are designed in a way 
that about 80% of the loaded rapamycin has eluted 
by 30 days [37, 38]. By contrast, paclitaxel-eluting 
Figures 2a and 2b. Rapamycin and paclitaxel increase tissue factor (TF) expres-
sion.
a) Rapamycin binds to the mammalial target of rapamycin (mTOR); mTOR is a 
downstream mediator of the phosphatidylinositol-3 kinase (PI-3K) pathway, 
which plays an inhibitory role in TF expression. Hence, by inhibiting mTOR, rapa-
mycin leads to an increase in TF protein expression and surface activity. b) Pacli-
taxel increases c-jun NH2-terminal kinase (JNK) activation leading to an enhanced 
TF protein expression as well as surface activity. Thus, paclitaxel directly activates 
a positive regulatory pathway of TF expression, while rapamycin upregulates TF by 
disinhibiting an inhibitory pathway. MKKs: MAP kinase kinases.
Abbildungen 2a und 2b. Rapamycin und Paclitaxel erhöhen die Expression von 
Tissue-Faktor (TF).
a) Rapamycin bindet an mTOR („mammalial target of rapamycin“); mTOR ist ein 
Downstream-Mediator des Phosphatidylinositol-3-Kinase-(PI-3K-)Signaltrans duk-
tionswegs, welcher eine inhibitorische Rolle in der TF-Induktion spielt. Über die 
Hemmung von mTOR führt Rapamycin somit zu einer Zunahme der TF-Proteinex-
pression und Oberflächenaktivität. b) Paclitaxel verstärkt die Aktivierung von JNK 
(„C-jun NH2-terminal kinase“), welche zu einer Erhöhung der Proteinexpression 
und Oberflächenaktivität von TF führt. Paclitaxel aktiviert somit direkt einen posi-
tiven Signaltransduktionsweg, während Rapamycin TF durch die Disinhibition eines 
hemmenden Signaltransduktionswegs induziert. MKKs: „MAP kinase kinases“.
a
b
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stents have a biphasic drug release profile in vitro 
with an initial burst during the first 48 h after im-
plantation followed by a sustained low-level release 
for at least 2 weeks [23]. Owing to their lipophilic 
properties, both rapamycin and paclitaxel easily 
penetrate cell walls leading to retention of the drugs 
in the arterial tissue [15, 21, 51]. Thus, TF induction 
in response to both rapamycin and paclitaxel may 
promote a prothrombotic environment after deploy-
ment of DES (Figure 1). In how far these findings 
truly translate into clinical practice, however, re-
quires further studies, in particular with respect to 
the extent and the spatiotemporal pattern of TF in-
duction in the arterial wall after DES deployment.
DES Induce Endothelial Dysfunction in the 
Distal Coronary Circulation
There is evidence that both rapamycin and paclitaxel 
may not only affect the vasculature at the site of stent 
implantation, but also in coronary artery segments 
distal to the stent. Indeed, long-term endothelial dys-
function of coronary artery segments distal to siroli-
mus-eluting stent, but not BMS, occurs as indicated 
by significant vasoconstriction in response to acetyl-
choline infusion [26]. Similarly, implantation of pac-
litaxel-eluting stents is associated with exercise-in-
duced vasoconstriction in the segments proximal and 
distal to the stent, while exercise-induced vasodila-
tion is observed after BMS placement [52]. Taken 
together, these findings indicate that drugs released 
from DES may affect the distal coronary vasculature 
facilitating coronary vasoconstriction and potentially 
contributing to no-reflow phenomena after stent de-
ployment.
Effect of the Stent Material in the Coronary 
Circulation
Certain stent materials appear to promote the de-
velopment of stent thrombosis. For example, im-
plantation of an open-cell versus a closed-cell stent 
resulted in greater platelet activation 30 days fol-
lowing implantation [22]. The stent strut thickness 
as well as the polymer type also appear to play an 
important role. Chronic eosinophilic infiltration of 
the arterial wall suggestive of a hypersensitivity re-
action has also been observed, probably in response 
to the nonerodable polymers of DES [29, 39]; most-
ly, these reactions occur > 4 months after DES im-
plantation (Figure 1) [29, 32]. While the polymer 
may have an effect on the coronary vasculature after 
DES placement, the causal relationship between 
polymer-induced inflammation and the incidence of 
late stent thrombosis has only been suggested in a 
minority of patients.
Design of Future Drug-Eluting Stents
The ideal DES inhibits restenosis without interfering 
with (or even expediting) reendothelialization, all on 
the basis of a biologically inert polymer. While sev-
eral novel approaches aim at improving currently 
available DES, no ideal combination of materials and 
drugs has yet been developed. One potential ap-
proach uses a simple chemical coating, such as titani-
um-nitride oxide, which diminishes platelet adhesion 
and fibrinogen binding as compared to BMS; whether 
this strategy will be effective against restenosis and 
stent thrombosis, however, remains to be studied in 
large clinical trials [56]. Coating of stents with agents 
facilitating reendothelialization after stent implanta-
tion may represent another feasible approach to re-
duce the thrombogenity of DES. In a porcine coro-
nary artery stenting model, stents loaded with an in-
tegrin-binding cyclic Arg-Gly-Asp peptide indeed 
accelerate endothelialization by attracting EPCs [5]. 
In humans, endothelial coverage is accelerated after 
implantation of stents coated with antibodies against 
CD34 designed to capture EPCs [1]. However, fur-
ther studies are needed to assess the long-term effi-
cacy and safety of these biologically active stents. A 
combination of substances accelerating endothelial 
healing (such as vascular endothelial growth factor 
and others) with established agents reducing resteno-
sis represents another promising approach.
Dimethyl sulfoxide (DMSO) may also represent 
an interesting therapeutic principle for DES coating. 
We recently demonstrated that DMSO prevents 
VSMC proliferation and migration; at the same time, 
DMSO reduces upregulation of TF in endothelial cells, 
vascular smooth muscle, and monocytes, and prevents 
thrombotic occlusion in vivo in a mouse carotid artery 
injury model [9]. Thus, DMSO may have the potential 
to inhibit both neointima formation and stent throm-
bosis, if loaded on a DES. Whether these promising 
first results hold true in a larger animal model and in 
humans, however, remains to be determined.
Summary and Conclusion
Once deployed, DES exert different biological ef-
fects in the coronary circulation. Importantly, their 
action is not confined to inhibition of migration and 
proliferation of VSMCs, i.e., important factors in 
neointima formation and the development of reste-
nosis, but extends to other cell types such as endothe-
lial cells. Indeed, both rapamycin and paclitaxel de-
crease endothelial cell migration and proliferation; in 
addition, the drugs induce endothelial TF expression 
through specific interaction with signal transduction 
mediators. Furthermore, DES decrease homing, pro-
liferation, and differentiation of EPCs, equally be-
lieved to be involved in endothelial regeneration af-
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ter stent implantation. Both rapamycin and paclitaxel 
have also been demonstrated to induce endothelial 
dysfunction in the distal coronary vasculature. Final-
ly, the polymer used for DES may be associated with 
hypersensitivity reactions which may, at least in some 
cases, promote stent thrombosis.
These undesired local side effects of DES in the 
vessel wall clearly demonstrate the need for improve-
ment of currently applied first-generation DES; in-
deed, these side effects appear particularly important 
in the light of the ongoing debate of a possibly in-
creased risk of stent thrombosis with DES as com-
pared to BMS. Hence, improvements of currently 
available systems as well as the introduction of novel 
treatment strategies are needed in order to advance 
the development toward the goal of preventing reste-
nosis without the cost of delayed endothelial healing 
and increased stent thrombogenity.
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